Abstract
Acipimox is a new lipid-lowering agent with long-lasting antilipolytic activity chemically related to nicotinic acid (1,2). The aim o f the present trial was to study the effect of acipimox on plasma lipid levels and its tolerability during long-term treatment in diabetic patients with hyperlipoproteinemia. The trial included investigation of any influence of the drug on glucose tolerance.
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Preview
Unable to display preview. Download preview PDF.
References
Fuccella, L et al (1980). Inhibition of lipolysis by nicotinic acid and by acipimox. CIin. Pharmacol. Ther., 28, 790.
Stirling, C et al (1985). Effects of acipimox, a nicotinic acid derivative, on lipolysis in human adipose tissue and cholesterol synthesis in human jejunal mucosa. Clin. Sci., 68, 83.
Parsons, W B et al (1961). Studies of nicotinic acid use in hypercholesterolemia: changes in hepatic function, carbohydrate tolerance and uric acid metabolism. Arch. Int. Med., 107, 653.
Pollack, H (1962). Nicotinic acid and diabetics. Diabetes, 11, 144.
Regal, H et al (1984). Effect of a single oral dose of acipimox on glucose metabolism after intravenous glucose load in obese patients. Drugs Exptl. Clin. Res., 10, 621.
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 1987 MTP Press Limited
About this chapter
Cite this chapter
Muggeo, M., Lavezzari, M., Montoro, C., Sacchetti, G. (1987). Long-term multicentre trial with acipimox in diabetic patients with hyperlipoproteinemia. In: Lenzi, S., Descovich, G.C. (eds) Atherosclerosis and Cardiovascular Diseases. Springer, Dordrecht. https://doi.org/10.1007/978-94-009-3205-0_62
Download citation
DOI: https://doi.org/10.1007/978-94-009-3205-0_62
Publisher Name: Springer, Dordrecht
Print ISBN: 978-94-010-7938-9
Online ISBN: 978-94-009-3205-0
eBook Packages: Springer Book Archive